MRSEI 2015 - 6C3

Gustave Roussy (GR) is coordinating efforts with five other European Comprehensive Cancer Centers (CCCs) to form a pan-European virtual e-CCC. Its objectives include launching clinical trials that refine patient stratification due to concomitant analysis of a) patient anti-tumoral immunity and b) the tumor genome. Resulting trials will benefit cancer patients by allowing the best possible combinations of drugs to be used against molecular targets, and by triggering re-activation of patient immune response to tumors. The project plans to collaborate with industrial and biopharmaceutical companies who have expressed their interest in participating in future projects/calls for proposals to support the network’s goals. Six European centers—Gustave Roussy (GR) Cancer Campus in FR, Cambridge Cancer Centre in UK, Karolinska Institute (KI) in Stockholm SE, Netherlands Cancer Institute (NKI) in Amsterdam NE, Val d’Hebron Institute of Oncology (VHIO) in Barcelona ES, and the German Cancer Research Centre & National Centre for Tumour Diseases (DKFZ/NCT) in Heidelberg DE—together form a working consortium, “6C3” whose goal is to address the cancer research-patient care continuum by uniting their translational research activities. Task Forces have already met to determine the next steps to take and assign action points & roles as follows: - Employing new methodologies in clinical trials - Harmonization of procedures to run common clinical trials - Exploring tumor heterogeneity in a defined tumor site and between tumor-different metastatic sites - Following therapeutic outcomes by analyzing circulating tumoral DNA - Genomics to inform clinical decision making - IT data platform/data warehouse and integrated predictive modeling tools - Clinical imaging to evaluate treatment response Work packages, led by each of the CCCs have been drafted with deliverables and milestones following the initial work done by the Task forces. Gustave Roussy, as Project Coordinator, has been one the first centers in France and Europe to initiate innovative trials based on genomics. In addition, the institute’s strengths in basic tumor immunology support its role as a leader in demonstrating the efficiency of different immune therapies, either alone, in combination, or associated with targeted therapies in metastatic melanoma. GR’s European Affairs Office has 13 years’ experience preparing & supporting 51 European Projects overall. The European Office—which meets regularly with National Contact Points—will support future 6C3 proposals both during the preparation for and reporting phases. The innovative discoveries stemming from the boon in translational research, new clinical trials, methods & tools (such as a data sharing platform) created by the network will all contribute to the eventual formation of a pan-European e-CCC. The “6C3” network will become a one-stop-shop for biopharmaceutical companies to perform innovative clinical trials across Europe. The complementary area(s) of expertise within the network will build local and global expertise and will ultimately have a positive impact on results generated by the project. GR is coordinating an effort that brings together the best CCCs in Europe and as such the proposal will help to raise France’s profile as a leader in of truly personalized medicine in oncology. This work unites various experts in private industry—from biopharmaceutical to clinical imaging and biological testing—a necessity to successfully develop novel treatments. Anticipated results must contribute to lowering societal costs and reducing toxicity to a minimum for cancer patients. Overall, the project aims to increase Europe’s attractiveness as a site to perform clinical trials. France will surely benefit from being a part of these efforts.